The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Orthopedic Implant Infection

Infection associated with orthopedic implanted hardware (prosthetic joints, fracture fixation hardware including plates, screws, intramedullary nails, external fixation, spinal hardware) representing one of the most challenging complications in orthopedic surgery; classified by timing (early < 3 months — typically intraoperative contamination, virulent organisms; delayed 3-24 months — typically intraoperative contamination, indolent organisms with biofilm; late > 24 months — typically hematogenous from distant infection); pathophysiology involves biofilm formation by bacteria on implant surface providing protection from antibiotics and immune system, with characteristic organisms (S. aureus including MRSA, coagulase-negative staphylococci including S. epidermidis, gram-negatives, anaerobes, polymicrobial in some cases); diagnosis requires high index of suspicion combined with clinical assessment (pain, drainage, swelling), serum markers (ESR, CRP, IL-6, alpha-defensin), imaging (radiography, MRI, nuclear medicine), and definitive cultures of synovial fluid (with cell count and culture) and intraoperative tissue/fluid samples (multiple, gold standard with at least 5 specimens for prosthetic joint); treatment usually requires combination of surgical intervention (one-stage exchange, two-stage exchange — current gold standard for chronic prosthetic joint infection, debridement antibiotics implant retention DAIR for early acute infections, lifelong suppressive antibiotics for poor surgical candidates) and prolonged antibiotic therapy targeting biofilm-active agents (rifampin combinations for staph, fluoroquinolones for gram-negatives), with success rates 70-95 percent depending on type of treatment, organism, host factors.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Ortopedi ve Travmatoloji department. Book Appointment →

What is Orthopedic Implant Infection?

Orthopedic implant infection refers to infection associated with orthopedic implanted hardware including prosthetic joints, fracture fixation devices (plates, screws, rods, intramedullary nails, external fixators), spinal hardware (cages, rods, screws), and other orthopedic implants. These infections represent one of the most challenging complications in orthopedic surgery with significant impact on quality of life, function, and healthcare costs. Treatment typically requires complex multidisciplinary management with prolonged antibiotic therapy and often surgical revision.

Epidemiology and incidence: 1) Prosthetic joint infection (PJI) — affects 0.5-2 percent of primary total joint arthroplasties (hip, knee), 1-3 percent of revisions, higher rates with rheumatoid arthritis and immunocompromised; with growing arthroplasty volumes worldwide, PJI represents major and growing problem; 2) Fracture fixation infection — 2-5 percent overall, varies by injury severity (open fractures up to 30 percent, especially Gustilo III), bone (tibia higher risk than femur), surgical approach; 3) Spinal hardware infection — 1-9 percent depending on type of surgery and risk factors; 4) Pin tract infection (external fixation) — 5-50 percent variable; 5) Total cost of PJI estimated at $1-2 billion annually in US.

Pathophysiology: 1) Biofilm formation — central concept; bacteria attach to implant surface, secrete extracellular polymeric substance (slime), form complex three-dimensional community; biofilm bacteria are: a) 10-1000 fold more resistant to antibiotics than planktonic forms; b) Less susceptible to phagocytosis and immune mechanisms; c) Have heterogeneous metabolic states (some dormant cells/persisters); d) Communicate via quorum sensing; e) Difficult to eradicate without removing the implant; f) Common biofilm-producers include S. epidermidis, S. aureus, P. aeruginosa, Candida; 2) Routes of contamination: a) Intraoperative contamination (most common — air, surgeon, instruments, patient skin flora) — typically presents early or delayed depending on virulence; b) Hematogenous spread — bacteria from distant infection (urinary tract, dental, skin) reach implant via bloodstream; typically presents late, > 2 years post-implantation; c) Direct extension from adjacent infection (rare); 3) Risk factors include host factors (diabetes, rheumatoid arthritis, immunosuppression, malnutrition, obesity, smoking, prior infection at surgical site), surgical factors (revision surgery, prolonged operative time, allogeneic blood transfusion, intra-articular injection within 3 months), implant-specific factors (cementless versus cemented, antibiotic-loaded cement, surface characteristics, design), and post-operative factors (wound healing problems, peri-prosthetic infection elsewhere, wound drainage > 5 days).

Classification systems: 1) Tsukayama classification by timing: a) Early postoperative infection (<3 months) — within first 3 months of surgery, typically caused by virulent organisms (S. aureus, gram-negatives) from intraoperative contamination, presents with acute symptoms — pain, drainage, fever; b) Delayed (chronic) infection (3-24 months) — typically caused by less virulent organisms (coagulase-negative staphylococci, S. epidermidis, Cutibacterium acnes) from intraoperative contamination, presents with insidious symptoms — chronic pain, mechanical symptoms; c) Late hematogenous infection (>24 months) — typically from distant infection (urinary tract, dental, skin), presents acutely; 2) Coventry classification — similar timing-based; 3) Musculoskeletal Infection Society (MSIS) criteria for prosthetic joint infection (definite versus probable based on multiple criteria including positive cultures, serology, synovial fluid analysis, histopathology, sinus tract); 4) International Consensus Meeting (ICM) criteria — updated definitions; 5) By organism — virulent (S. aureus, gram-negatives) versus less virulent (coagulase-negative staphylococci, P. acnes); virulent typically requires more aggressive surgical management; 6) By extent — superficial wound infection (above fascia) versus deep periprosthetic infection (below fascia, involving implant).

Symptoms

Pain at site of implant (chronic, constant, may worsen at night)
Drainage from surgical wound (purulent, serous, bloody)
Sinus tract (chronic draining tract from implant)
Wound dehiscence (separation of surgical wound)
Erythema and warmth over implant site
Swelling around implant
Decreased range of motion of joint with implant
Mechanical symptoms (loosening, instability, locking)
Fever (variable — more common in early infection)
Chills and rigors
Fatigue and malaise
Decreased function of affected limb
Foul-smelling discharge (in chronic infection)
Visible bone or hardware at wound site
Persistent or worsening symptoms after expected healing time
Recent dental work or distant infection in late hematogenous presentation
Recent urinary tract infection or surgery (hematogenous risk)
Recent IV drug use (hematogenous risk)
Wound healing problems
Signs of systemic infection (sepsis criteria)
Reduced wound margins after closure
Persistent serous drainage > 5 days
Premature implant loosening or failure
Joint instability after total joint replacement
Recurrent infection at same location

Risk Factors

Diabetes mellitus (especially poorly controlled)
Rheumatoid arthritis
Immunosuppression (HIV, transplant, chemotherapy, biologics)
Malnutrition (low albumin)
Obesity (BMI > 35)
Smoking
Alcohol abuse
Prior surgical site infection at same location
Revision surgery (vs. primary)
Intra-articular injection (within 3 months pre-surgery)
Distant active infection at time of surgery
Prolonged operative time (> 3 hours)
Allogeneic blood transfusion
Wound healing problems post-operatively
Wound drainage > 5 days
Hematoma formation
Open fracture (Gustilo classification, especially III)
Soft tissue compromise at fracture site
Multiple comorbidities
Older age (immunosenescence)
Poorly controlled diabetes (HbA1c > 7-8 percent)
Drug abuse (IV drug use — hematogenous spread)
Recent dental work without prophylaxis (high-risk patients)
Recent urinary tract infection or instrumentation
Skin infection prior to surgery
Chronic kidney disease
Heart disease
Female sex (some studies)
African American race (in US studies)
Cementless implants (variable evidence)
Surgical complications during procedure

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New pain at implant site after orthopedic surgery
  • Persistent or worsening pain after implant
  • Drainage from surgical wound
  • Wound dehiscence
  • Sinus tract draining from wound
  • Fever after orthopedic surgery (especially after first 48 hours)
  • Redness or swelling at surgical site
  • Visible bone or hardware at wound
  • Decreased function of joint with implant
  • Mechanical symptoms (loosening, instability, locking)
  • Recent dental procedure or distant infection in patient with implant (late hematogenous risk)
  • Recent UTI or urinary instrumentation (hematogenous risk)
  • Recent IV drug use
  • Wound healing problems beyond expected
  • Premature implant loosening on imaging
  • Joint instability after TJR
  • Recurrent infection at implant site
  • Symptoms of sepsis with implant in place (URGENT)
  • Pre-procedural evaluation in patient with implant
  • Pre-dental work prophylactic considerations in high-risk implant patients
  • Routine follow-up of orthopedic implant
  • Concerns about expected versus actual recovery

Treatment Methods

01
Initial assessment: 1) Comprehensive history including details of original surgery (date, indication, surgeon, hospital), prior infections at site, comorbidities (diabetes, rheumatoid arthritis, immunosuppression), risk factors for hematogenous spread (recent dental, urinary procedures, distant infections, IV drug use), current medications, allergies; 2) Physical examination — wound assessment, range of motion, neurovascular examination, signs of systemic infection; 3) Pain pattern (chronic constant suggests infection versus mechanical), functional limitation; 4) Photographic documentation; 5) Recent imaging review
02
Diagnostic workup for prosthetic joint infection (PJI): 1) Serum markers — ESR, CRP (elevated in 90+ percent of PJI), IL-6 emerging marker, D-dimer, complete blood count, comprehensive metabolic panel; 2) Imaging — plain radiography (loosening, periprosthetic lucency >2mm, periprosthetic fracture, periosteal reaction), MRI with metal artifact reduction sequences (MARS) for soft tissue evaluation, CT for bony detail, nuclear medicine (bone scan with technetium, gallium scan, indium-labeled WBC scan, FDG-PET — variable utility); 3) Synovial fluid analysis — joint aspiration with: a) Total cell count > 3000-5000/mL (chronic) or > 10000/mL (acute) for prosthetic joint; b) Neutrophils > 70 percent of cell count; c) Synovial culture (positive in 60-80 percent of confirmed PJI); d) Synovial alpha-defensin (highly specific 95+ percent, sensitivity 75-90 percent); e) Synovial WBC esterase strip (rapid bedside test); f) Synovial CRP (emerging); 4) Histopathology — intraoperative frozen section >5 PMN per high power field consistent with infection (Feldman criteria); 5) Tissue cultures — multiple specimens (5+ optimal for PJI), from different periprosthetic locations including capsule, synovium, periprosthetic bone; cultures held 14 days for slow-growing organisms (P. acnes); 6) Sonication of explanted prosthesis with culture of sonicate fluid (more sensitive than periprosthetic tissue cultures particularly for biofilm-encased organisms); 7) Molecular methods — PCR, 16S rRNA gene sequencing for culture-negative infections (sensitivity 50-70 percent in negative cultures); 8) MSIS or ICM diagnostic criteria for definite versus probable diagnosis
03
Treatment of acute prosthetic joint infection (early or late hematogenous): 1) DAIR (Debridement, Antibiotics, Implant Retention) — preferred for acute infection within 4 weeks of symptoms with stable implant; success rate 60-85 percent depending on organism (S. aureus 50-60 percent, gram-negatives 30-40 percent), modular component exchange (polyethylene insert, head); requires aggressive surgical debridement, exchange of all modular components, lavage with multiple liters, antibiotic spacers if available; 2) Surgical principles — open arthrotomy with extensive synovectomy and debridement, removal of all foreign material possible (cement, debris), thorough lavage, pulse jet lavage, irrigation with antibiotic solutions; 3) Antibiotic therapy — empirical until cultures (vancomycin + gram-negative coverage), targeted therapy 4-6 weeks IV followed by oral total 3-6 months; 4) DAIR in patients with multiple comorbidities, late hematogenous infection (within 3 weeks), specific organism considerations, with stable implant; 5) When DAIR contraindicated — chronic infection > 4 weeks symptoms, loose implant, fistula, soft tissue compromise, virulent organism (MRSA, gram-negatives), high host risk factors
04
Treatment of chronic prosthetic joint infection: 1) Two-stage revision arthroplasty (gold standard) — Stage 1: Removal of all components (femoral and acetabular for hip, tibial and femoral for knee), thorough debridement, antibiotic-impregnated cement spacer placement (PMMA with high-dose vancomycin and tobramycin), 6 weeks IV antibiotics followed by 2 weeks off antibiotics with monitoring (ESR, CRP normalization); Stage 2: Aspiration and culture confirmation of infection eradication, then revision arthroplasty with new components; success rate 80-95 percent; 2) One-stage revision arthroplasty (selected cases) — single procedure with explantation, debridement, immediate reimplantation with antibiotic-loaded cement; reserved for ideal candidates (sensitive organism with good biofilm activity, healthy soft tissue, patient with multiple comorbidities); success rate 75-85 percent in selected cases; 3) Resection arthroplasty (Girdlestone for hip, knee fusion or resection for knee) — for refractory infection, severely compromised host or soft tissue, multiple failed revision attempts; provides infection control but significant functional limitation; 4) Arthrodesis (joint fusion) — for refractory infection of knee, particularly in younger active patients; 5) Suppressive antibiotic therapy — lifelong oral antibiotics for poor surgical candidates with stable infection; not curative but maintains function with infection suppression; 6) Amputation — for refractory infection with severe vascular compromise, severe deformity, multidrug-resistant infection in immunocompromised patient
05
Treatment of fracture fixation infection: 1) Acute (<2 weeks symptoms) with stable fixation — debridement and retention of hardware (DAIR equivalent); 2) Hardware retention may be possible if fixation is stable, fracture not yet healed (need for stability), and infection acute; 3) Chronic infection with healed fracture — hardware removal followed by treatment of any residual osteomyelitis; 4) Chronic with non-healed fracture — exchange of hardware with stable construct, debridement, antibiotics; 5) External fixation may be used as temporary fixation during treatment of bone infection; 6) Bone reconstruction techniques as needed for segmental defects (Ilizarov bone transport, vascularized fibula, autogenous cancellous grafting); 7) Soft tissue coverage (flap procedures) when needed
06
Antibiotic therapy: 1) Empirical therapy based on suspected organisms — vancomycin for MRSA coverage plus broad-spectrum gram-negative coverage until culture sensitivities; 2) Targeted therapy after culture sensitivities; 3) Duration: a) DAIR — 4-6 weeks IV antibiotics followed by oral suppression up to 3-6 months total; b) Two-stage revision — 6 weeks IV antibiotics during interval, may be followed by oral therapy; c) One-stage revision — variable, typically 6-12 weeks combined IV and oral; d) Suppressive therapy — lifelong; 4) Specific organism considerations: a) MRSA — vancomycin, daptomycin, linezolid; b) MSSA — nafcillin, cefazolin, oxacillin; c) Pseudomonas — anti-pseudomonal beta-lactam plus aminoglycoside or fluoroquinolone; d) Streptococcus — penicillin G, ceftriaxone; e) Cutibacterium acnes — penicillin or vancomycin (sometimes combined with rifampin for shoulder PJI); f) Enterobacteriaceae — third generation cephalosporin, beta-lactam-beta-lactamase inhibitor, fluoroquinolone (oral); 5) Combination therapy with rifampin (for biofilm-producing organisms — staphylococci) — rifampin combinations are essential for staph PJI when implant retained; 6) Outpatient parenteral antibiotic therapy (OPAT) for completion of IV therapy; 7) Oral antibiotics with good bone penetration after IV phase — fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), linezolid, doxycycline, trimethoprim-sulfamethoxazole, clindamycin, metronidazole
07
Specific considerations for prosthetic joint infection: 1) Multidisciplinary approach essential including infectious disease specialist, orthopedic surgeon, plastic surgery for soft tissue coverage, nutritional support, social work; 2) Patient counseling on multiple stages, treatment duration (6+ months for two-stage), functional limitations during treatment, possibility of permanent functional impairment; 3) Optimization of medical comorbidities prior to staged procedures (diabetes management, nutritional optimization, smoking cessation); 4) Soft tissue coverage requirements — flap procedures for compromised soft tissue (gastrocnemius for knee, soleus for tibia); 5) Functional rehabilitation throughout treatment; 6) Long-term follow-up surveillance for recurrence; 7) Infection prevention prophylaxis in subsequent dental, urinary, surgical procedures (selected high-risk patients); 8) Bone reconstruction options for severely affected joints (massive bone loss may require custom implants, allografts, megaprosthesis, fusion)
08
Prevention strategies: 1) Pre-operative — antibiotic prophylaxis (cefazolin or alternative, ideally within 60 min of incision), MRSA screening and decolonization in high-risk patients (intranasal mupirocin, chlorhexidine showers), optimization of comorbidities (HbA1c < 7-8 percent, smoking cessation 4-8 weeks pre-op, weight loss, nutritional support, dental care); 2) Intraoperative — surgical hand scrubbing, sterile technique, laminar flow rooms, body exhaust suits in joint replacement, antibiotic-loaded cement, double-gloving, closed wound management; 3) Postoperative — wound care, prevention of hematoma, prompt management of wound drainage > 5 days, prophylactic antibiotics for high-risk patients during dental and other procedures (prosthetic joint patients within 2 years post-op or compromised host); 4) Patient education on early signs of infection, when to seek care, lifestyle modifications; 5) Surveillance protocols
09
Long-term outcomes and prognosis: 1) Success rates by treatment type: a) DAIR for acute PJI — 60-85 percent (better for acute and S. aureus, worse for chronic and resistant organisms); b) Two-stage revision — 80-95 percent for chronic PJI; c) One-stage revision — 75-85 percent in selected patients; d) Suppressive antibiotics — 50-70 percent maintenance of function; 2) Functional outcomes following successful infection treatment — 70-85 percent return to pre-infection function for two-stage revisions, with longer recovery (12-18 months) compared to primary procedures; 3) Recurrence rate 5-30 percent depending on treatment, organism, host factors; 4) Mortality rate for prosthetic joint infection significant — 5-7 percent at 1 year, 20+ percent at 5 years (multifactorial); 5) Quality of life impact — significant during treatment with multiple operations, prolonged immobilization, antibiotics; functional outcomes often acceptable in successful cases; 6) Patient must understand realistic expectations of staged treatment, possible recurrence, need for compliance with prolonged antibiotic therapy; 7) Continued research into biofilm-disrupting agents, novel antimicrobial strategies, antibiofilm coatings on implants, immunomodulation, single-stage treatment optimization, novel surgical techniques

Which Department to Visit?

You can visit our Ortopedi ve Travmatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Ortopedi ve Travmatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Low Back Pain and Lumbar Disc Herniation

Ortopedi ve Travmatoloji

Lumbar disc herniation occurs when the outer layer of the disc between the vertebrae tears and the inner part presses on nerve tissue, causing low back and leg pain.

Cervical Disc Herniation

Ortopedi ve Travmatoloji

Cervical disc herniation is a condition in which the disc between the vertebrae in the neck region presses on a nerve root or the spinal cord, causing neck, shoulder, and arm pain.

Knee Pain and Meniscus Tear

Ortopedi ve Travmatoloji

Meniscus tear is a tearing of the cartilage structures in the knee joint as a result of a sudden twisting movement or degeneration and is one of the most common causes of knee pain.

Shoulder Pain and Frozen Shoulder

Ortopedi ve Travmatoloji

Frozen shoulder (adhesive capsulitis) is a chronic condition characterized by inflammation and thickening of the shoulder joint capsule, causing restriction of movement in all directions and severe pain.

Bone Fractures

Ortopedi ve Travmatoloji

A fracture is partial or complete disruption of the integrity of bone tissue due to an external force or bone disease, and it can occur at any age.

Wrist Fracture (Distal Radius Fracture)

Ortopedi ve Travmatoloji

Distal radius fracture is one of the most common reasons for emergency room visits; it occurs when the radius bone fractures at the wrist end due to the hand being planted on the ground during a fall.

Hip Fracture

Ortopedi ve Travmatoloji

Hip fracture is a serious fracture mostly occurring in elderly individuals with osteoporosis due to a fall in the femoral neck or trochanteric region, and early surgical treatment is life-saving.

Ankle Sprain

Ortopedi ve Travmatoloji

Ankle sprain is a partial or complete tear of the ankle ligaments, most commonly involving the lateral ligament complex (ATFL, CFL, PTFL) after an inversion injury.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.